

## IMMUNITY, ANGIOGENESIS AND TISSUE REMODELING

Prof. Dr. Christian Stockmann

University of Zurich, Institute of Anatomy  
Winterthurerstrasse 190, 8057 Zürich

[christian.stockmann@uzh.ch](mailto:christian.stockmann@uzh.ch)

[www.anatomy.uzh.ch/en/research/stockmann.html](http://www.anatomy.uzh.ch/en/research/stockmann.html)



**KEYWORDS** — Microenvironment, hypoxia, fibrosis, immune surveillance

### SUMMARY & MISSION STATEMENT

We aim to exploit the hypoxic response in Natural Killer (NK) cells to provide a novel therapeutic paradigm for the management of organ fibrosis and cancer.

### OVERVIEW

Organ fibrosis as well as tumor progression show pathological features that are reminiscent of a classical wound healing response. Therefore, our work is based on the hypothesis that wound healing, organ fibrosis and tumor progression share strong mechanistic links. The prominent features of these processes are infiltration of immune cells and subsequent remodeling of the vasculature in response to hypoxia (low oxygen). Hypoxia-inducible transcription factors (HIFs) are central mediators of cellular adaptation to low oxygen (hypoxia). NK cells are key for immune surveillance in cancer and pre-cancerous types of organ fibrosis, due to unique cytotoxic properties. Our recent results indicate that HIF-deficiency impairs NK cell immune surveillance. We, therefore, hypothesize first, that HIF signaling is critical for NK cell performance, and second, that manipulating the HIF pathway in NK cells is a novel therapeutic target in cancer and organ fibrosis. Based on innovative murine disease models combined with genetic, NK cell-specific loss and gain of function approaches for HIFs, elaborated in vivo real time imaging techniques, the successful candidates will define the role of the hypoxic response in NK cells during organ fibrosis and tumor progression.

### SELECTED CANCER RELATED PUBLICATIONS


Loss of HIF-1 $\alpha$  in Natural Killer cells inhibits tumour growth by stimulating non-productive angiogenesis. Krzywinska E, Kantari-Mimoun C, Kerdiles Y, Gotthardt D, Castells M, Haubold J, Millien C, Viel T, Tavitian B, Fandrey J, Vivier E, Sexl V, Stockmann C. **Nat Commun** 2017 Aug 19;7:12528

Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. Klose K, Krzywinska E, Castells M, Gotthardt D, Putz EM, Kantari-Mimoun C, Chikdene N, Meinecke AK, Schrödter K, Helfrich I, Fandrey J, Sexl V, Stockmann C. **Nat Commun** 2016 Aug 19;7:12528

STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. Gotthardt D, Putz EM, Grundschober E, Prchal-Murphy M, Straka E, Kudweis P, Heller G, Bago-Horvath Z, Witalisz-Siepracka A, Cumaraswamy AA, Gunning PT, Strobl B, Müller M, Moriggl R, Stockmann C, Sexl V. **Cancer Discov.** 2016 Apr;6(4):414-29.

Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, Goldrath AW, Johnson RS. **Cancer Res** 2010;70:7465-75.

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresch DA, Johnson RS. **Nature** 2008;456:814-8.



**Inflammation and vascular remodeling connect cancer, wound healing and fibrosis.**